Study of Immune Cells and Lymph Nodes in Adults with Kidney Cancer to Understand Tumor Biology and Treatment Responses

What this Trial Is About

Researchers are studying the behavior and characteristics of T cells in tumor draining lymph nodes from patients with Renal Cell Carcinoma RCC. The goal is to better understand T cell priming and movement in kidney cancer to support biomarker discovery, identify new treatment targets, and explore the genetic basis of kidney cancers. This pilot study collects data and biospecimens to support current and future kidney cancer research. Participants with confirmed or suspected kidney cancer will provide tissue samples at key treatment points, including before treatment, during response, or if resistance or toxicity occurs. Samples include tumor tissue, adjacent normal kidney tissue, draining and regional lymph nodes, and blood collected during routine care or clinical trials. These specimens will be analyzed to study immune function and cancer biology. During the study, participants will undergo tissue and blood collection linked to their regular treatment or surgery. Researchers will perform molecular profiling of tumor and lymph node tissues over 24 months, examine responses and resistance to anti-cancer therapies, and study biomarkers predicting treatment toxicities. The study uses samples collected during standard care or trial procedures, with no additional treatment interventions. Participation may last up to several years depending on treatment and sample collection schedules.

Investigation of Lymph Node Biology in Kidney Cancer